Breast Cancer Research

Breast Cancer Research

Research into breast cancer at Penn State Cancer Institute is conducted by a dedicated breast cancer team. See current clinical trials and members of that team here.

Clinical Trials

Umbrella Long-term Follow-up Protocol
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination with Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
Role of TRP Channel Isoforms in Breast Cancer
An Observational Trial of the Phase I and II Metabolism Profile of Exemestane in Breast Cancer Patients
Clinicopathologic Study of Breast Cancer
Sirtuin 3 (SIRT3): A Novel Predictive Biomarker for Tamoxifen Resistance
Predicting Breast Cancer Metastasis: Signaling Pathway Biomarker Identification Using Reverse Phase Protein Microarray (RPMA) Technology
Research into breast cancer at Penn State Cancer Institute is conducted by a dedicated breast cancer team. See current clinical trials and members of that team here.
Umbrella Long-term Follow-up Protocol
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination with Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
Role of TRP Channel Isoforms in Breast Cancer
An Observational Trial of the Phase I and II Metabolism Profile of Exemestane in Breast Cancer Patients
Clinicopathologic Study of Breast Cancer
Sirtuin 3 (SIRT3): A Novel Predictive Biomarker for Tamoxifen Resistance
Predicting Breast Cancer Metastasis: Signaling Pathway Biomarker Identification Using Reverse Phase Protein Microarray (RPMA) Technology

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)